Prof
Paul
Cahill

Primary Department
School of Biotechnology
Role
Professor
Phone number: 01 700
8466
Campus
Glasnevin Campus
Room Number
X209

Academic biography

  • 1990-1991: Post Doctoral Fellow, Department of Pharmacology, New York Medical College, Valhalla, NY, USA
  • 1991-1992:  Research Associate, Department of Physiology & Biophysics, University of Tennessee, Memphis, TN, USA,
  • 1992-1995: Instructor, Department of Surgery, Johns Hopkins University Hospital, Baltimore MD, USA
  • 1995-1997: Assistant Professor, Department of Surgery, Georgetown University, Washington DC, USA
  • 1997-1999: Associate Professor, Department of Surgery, Georgetown University, Washington DC, USA
  • 1999-2000: Professor of Surgery, University of Rochester Medical Center, Rochester NY, USA
  • 1999-2005: Adjunct Professor, Department of Surgery, University of Rochester Medical Center, Rochester NY, USA
  • 1999-2001: Wellcome Trust New Blood Fellow/Senior Lecturer, School of Biotechnology, DCU
  • 2001-2006: Director, Vascular Health Research Centre, DCU, 
  • 2001-2015: Associate Professor, School of Biotechnology, DCU,
  • 2016-to date: Full Professor and Chair of Vascular Biology & Therapeutics, School of Biotechnology, DCU

Research interests

Cardiovascular diseases remain a major cause of mortality worldwide.  Vascular biology is an exciting and rapidly advancing area of biomedical research that has led to significant insights into the treatment not only of vascular diseases such as atherosclerosis, arteriosclerosis, in-stent restenosis and hypertension, but also diabetes and tumor development.  

Arteriosclerosis is an important age-dependent disease that encompasses atherosclerosis, in-stent restenosis (ISR), pulmonary hypertension, autologous bypass grafting and transplant arteriosclerosis. Endothelial dysfunction and the proliferation of vascular smooth muscle cell (vSMC)-like cells is a critical event in the pathology of vascular disease leading to intimal-medial thickening (IMT), lipid retention and vessel remodelling. An important aspect in guiding clinical decision-making is the detection of biomarkers of early cardiovascular risk. Crucially, relevant biomarkers need to be good indicators of injury which change in their circulating concentrations or structure, signalling functional disturbances.

Extracellular vesicles (EVs) are small membrane-bound vesicles secreted by cells that contain numerous bioactive molecules and act as a means of intercellular communication between different cell populations to maintain tissue homeostasis, gene regulation in recipient cells and the adaptive response to stress.


MAJOR RESEARCH AREAS:
Development of a pipeline for the generation of novel, multitargeted, next generation pleiotropic cell therapy biologics derived from allogeneic immortalized human bone-marrow derived MSCsPoint-of-Care Diagnostics (POCD) for subclinical arteriosclerotic disease using exosomal profilingEndothelial derived extracellular vesicles (EVs) following endothelial dysfunction - dictating the phenotype of resident vascular stem cells, smooth muscle cells and adventitial cells during adaptive lesion formation and progression of arteriosclerotic disease.Gene regulatory networks (Notch and Hedgehog) that control resident vascular stem cell fate - myogenic, osteogenic, adipogenic, vasculogenic and myeloid differentiationMechanical stimuli (shear stress, cyclic strain and pressure) and developmental gene regulatory network control of vascular smooth muscle and endothelial cell phenotype and fate.Lineage tracing analysis and epigenetic profiling of resident vascular stem cells during arteriosclerotic disease progressionSingle cell auto-fluorescence photonic emissions and vibrational spectroscopy to discriminate vascular cell phenotypes using supervised machine learningMagnetic nanoparticles as drug-delivery platform for vascular stentsVascular tissue engineering